China, Oct. 28 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Real-World Effectiveness and Safety of Nefecon for Primary IgA Nephropathy'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600135269
Registration Time: 2026/10/28
Type: Observational study
Primary Sponsor: Shanghai General Hospital
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=344068
Published by HT Digital Content Services with permission from Health Daily Digest....